Why Is Sanofi Betting on MannKind Corporation's Afrezza?
Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?
Is It Time to Buy Top Dividend Stock Sanofi?
French biopharma Sanofi offers one of the highest-dividend yields in the healthcare sector. But is the stock a buy?